-transparent.png){kind=logo}
Imipenem-cilastatin (imipenem 1 to 4 g/day) was administered to patients with severe infections accompanying granulocytopenia in hematological malignancies. Monotherapy with imipenem-cilastatin was effective in 62.1% of the patients, and also effective even they were severely neutropenic. When imipenem-cilastatin was administered as the first-choice therapy, the efficacy was much better, at 73.3%. Both Gram-positive and Gram-negative infections were curable by the monotherapy with imipenem-cilastatin.
Related Publications
A Urabe, and
F Takaku, and
H Mizoguchi
January 1987,
Scandinavian journal of infectious diseases. Supplementum,
A Urabe, and
F Takaku, and
H Mizoguchi
March 1993,
The Japanese journal of antibiotics,
A Urabe, and
F Takaku, and
H Mizoguchi
August 1990,
The Japanese journal of antibiotics,
A Urabe, and
F Takaku, and
H Mizoguchi
April 1990,
Presse medicale (Paris, France : 1983),
A Urabe, and
F Takaku, and
H Mizoguchi
August 1991,
The Japanese journal of antibiotics,
A Urabe, and
F Takaku, and
H Mizoguchi
November 1997,
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology,
A Urabe, and
F Takaku, and
H Mizoguchi
April 1988,
Chemioterapia : international journal of the Mediterranean Society of Chemotherapy,
A Urabe, and
F Takaku, and
H Mizoguchi
January 1989,
Chemotherapy,
A Urabe, and
F Takaku, and
H Mizoguchi
December 1989,
The Japanese journal of antibiotics,
A Urabe, and
F Takaku, and
H Mizoguchi
December 1986,
The Journal of antimicrobial chemotherapy,
